The European Commission press release adds: "The consortium has already virtually tested 400 000 molecules using its supercomputers. 7 000 molecules were preselected and further tested 'in vitro'.
Raloxifene emerged as a promising molecule: according to the project, it could be effective in blocking the replication of the virus in cells, and could thus hold up the progression of the disease."
According to the project partners, Raloxifene "is well-tolerated with a known safety profile," as explained in a press release on the project website. The EXSCALATE4CoV consortium is in discussions with the European Medicines Agency for establishing "the fastest path to clinical trials in humans."
